Elilly将2024年的收入预测削减为45B, 原因是其减重药品销售疲软。 Eli Lilly cuts 2024 revenue forecast to $45B due to sluggish sales of its weight-loss drugs.

Elilly将其2024年的收入预测降至约450亿美元,因为其减重药品Mounjaro和Zepbound的销售比预期慢。 Eli Lilly lowered its 2024 revenue forecast to about $45 billion due to slower-than-expected sales of its weight-loss drugs, Mounjaro and Zepbound. 该公司的股票因此下跌。 The company's stock dropped as a result. 尽管遭遇挫折,莉莉预计2025年收入将增长32%,预计销售额在580亿至610亿美元之间。 Despite the setback, Lilly expects revenue to grow by 32% in 2025, projecting sales between $58 billion and $61 billion. 该公司还计划在2025年上半年将这些药物的产量增加60%。 The company also plans to increase production of these drugs by 60% in the first half of 2025.